Jamshidi, Khodamorad, Gharehdaghi, Mohamad, Hajialiloo, Sami Sam, Mirkazemi, Masoud, Ghaffarzadehgan, Kamran, Izanloo, Azra. (1397). Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review. , 6(4), 260-268. doi: 10.22038/abjs.2018.25254.1665
Khodamorad Jamshidi; Mohamad Gharehdaghi; Sami Sam Hajialiloo; Masoud Mirkazemi; Kamran Ghaffarzadehgan; Azra Izanloo. "Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review". , 6, 4, 1397, 260-268. doi: 10.22038/abjs.2018.25254.1665
Jamshidi, Khodamorad, Gharehdaghi, Mohamad, Hajialiloo, Sami Sam, Mirkazemi, Masoud, Ghaffarzadehgan, Kamran, Izanloo, Azra. (1397). 'Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review', , 6(4), pp. 260-268. doi: 10.22038/abjs.2018.25254.1665
Jamshidi, Khodamorad, Gharehdaghi, Mohamad, Hajialiloo, Sami Sam, Mirkazemi, Masoud, Ghaffarzadehgan, Kamran, Izanloo, Azra. Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review. , 1397; 6(4): 260-268. doi: 10.22038/abjs.2018.25254.1665

Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review

The Archives of Bone and Joint Surgery
مقاله 3، دوره 6، شماره 4، مهر 2018، صفحه 260-268    اصل مقاله (1.14 M)
نوع مقاله: SYSTEMATIC REVIEW
شناسه دیجیتال (DOI): 10.22038/abjs.2018.25254.1665
نویسندگان
Khodamorad Jamshidi1؛ Mohamad Gharehdaghi2؛ Sami Sam Hajialiloo1؛ Masoud Mirkazemi1؛ Kamran Ghaffarzadehgan3؛ Azra Izanloo* 3
1Bone and Joint Reconstruction Research Center, Shafa Orthopedic Hospital, Iran University of Medical Sciences, Tehran, Iran
2Orthopedic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
3Razavi Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran
چکیده
Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lower
morbidity. However, some studies have reported several complications for this drug. So, this systematic review
was performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity of
giant cell tumor and skeletal-related events (SRE) in affected patients with giant cell tumor of bone (GCTB) and its
recurrence.
We explored studies in PubMed, and Cochrane Library. For this purpose, articles of various levels were retrieved
until October 22, 2016. Two reviewers assessed the articles independently based on predefined criteria to extract the
relevant data. Primary outcomes associated with skeletal-related event, overall survival, and secondary outcomes
such as pain, quality of life and adverse events were evaluated and analyzed.
The total population of this meta-analysis consisted of 686 patients. Of this population, 55% had primary GCTB and
45% had giant cell tumor recurrence, with 2% experiencing secondary recurrence.
The results showed the effectiveness of Denosumab in reducing the tumor size due to inhibiting the Osteoclastogenesis.
Denosumab didnot show any effect on reducing tumor recurrence, but, in cases where complete tumor surgery is
not possible and tumor residuals may remain, Denosumab can be helpful. Also, the clinicians should consider the
risk benefit of Denosumab.
کلیدواژه‌ها
Denosumab؛ Giant cell tumor of bone؛ Meta-analysis؛ Recurrence؛ Systematic review
مراجع
آمار
تعداد مشاهده مقاله: 1,202
تعداد دریافت فایل اصل مقاله: 1,265
دانشگاه علوم پزشکی مشهد
آمار
تعداد نشریات29
تعداد شماره‌ها2,324
تعداد مقالات24,861
تعداد مشاهده مقاله82,793,332
تعداد دریافت فایل اصل مقاله45,851,552
اخبار نشریات